A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

NCT04967248 · clinicaltrials.gov ↗

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Low recruitment

Conditions

Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Interventions

OTHER: Alpelisib
OTHER: Fulvestrant

Sponsor

Novartis Pharmaceuticals